Skip to main content
Top
Published in: Journal of Radiation Oncology 2/2017

01-06-2017 | Original Research

Improved infield response rates and overall survival in patients with metastatic melanoma receiving higher biological equivalent doses of radiation with ipilimumab

Authors: Heath B. Mackley, Jason Liu, Junjia Zhu, Henry Wagner, Giampaolo Talamo, Todd D. Schell, Colette Pameijer, Rogerio I. Neves, Bryan Anderson, Kathleen M. Kokolus, Jeffrey Sivik, Carol A. Mallon, Kristian M. Koller, Joseph J. Drabick

Published in: Journal of Radiation Oncology | Issue 2/2017

Login to get access

Abstract

Objective

There is a growing body of evidence that combining radiotherapy with ipilimumab might improve the survival and response rates in patients with metastatic melanoma. However, the patient and treatment variables that predict for improved outcomes have not been well defined.

Methods

We conducted a retrospective analysis of 69 patients treated with ipilimumab and radiotherapy for metastatic melanoma at a single institution from May 2011 to June 2015. Demographic, clinical, and treatment factors were recorded, and end points of interest included infield and global complete response (CR) after the completion of radiation and ipilimumab based on the RECIST criteria (v1.1), and overall survival (OS). A bivariate and multivariate analysis was then performed to assess the relationship between outcomes and patient variables.

Results

In the multivariate analysis, infield CR was significantly associated with completing a full course of ipilimumab, a higher BED, and a smaller size of metastatic area treated. Global CR was significantly associated with increased age and giving radiotherapy to all areas of disease. OS was significantly associated with completing a full course of ipilimumab and a higher BED. Interestingly, after a multivariate analysis, higher BED was associated with an improved infield CR (p = 0.0281) and was not associated with an improved global CR (p = 0.5284) but was marginally associated with improved OS (p = 0.0545).

Conclusion

Our findings suggest that the rate of a global CR is independent of the dose of radiation given, but the rate of infield CR and OS might improve with higher doses.
Literature
8.
go back to reference Theurich S, Rothschild SI, Hoffmann M et al (2016) Local tumor treatment in combination with systemic Ipilimumab immunotherapy prolongs overall survival in patients with advanced malignant melanoma. Cancer Immunol Res 2997:1–12. doi:10.1158/2326-6066.CIR-15-0156 Theurich S, Rothschild SI, Hoffmann M et al (2016) Local tumor treatment in combination with systemic Ipilimumab immunotherapy prolongs overall survival in patients with advanced malignant melanoma. Cancer Immunol Res 2997:1–12. doi:10.​1158/​2326-6066.​CIR-15-0156
14.
18.
go back to reference Koller KM, Mackley HB, Liu J, et al. Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone. Cancer Biol Ther. 2016;0(0):1–7. doi:10.1080/15384047.2016.1264543. Koller KM, Mackley HB, Liu J, et al. Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone. Cancer Biol Ther. 2016;0(0):1–7. doi:10.​1080/​15384047.​2016.​1264543.
23.
go back to reference Overgaard J, Overgaard M, Hansen PV, von der Maase H (1986) Some factors of importance in the radiation treatment of malignant melanoma. Radiother Oncol 5(3):183–192CrossRefPubMed Overgaard J, Overgaard M, Hansen PV, von der Maase H (1986) Some factors of importance in the radiation treatment of malignant melanoma. Radiother Oncol 5(3):183–192CrossRefPubMed
24.
go back to reference Overgaard J, Gonzalez Gonzalez D, Hulshof MC et al (1995) Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. Lancet 345(8949):540–543. doi:10.1016/S0140-6736(95)90463-8 CrossRefPubMed Overgaard J, Gonzalez Gonzalez D, Hulshof MC et al (1995) Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. Lancet 345(8949):540–543. doi:10.​1016/​S0140-6736(95)90463-8 CrossRefPubMed
30.
Metadata
Title
Improved infield response rates and overall survival in patients with metastatic melanoma receiving higher biological equivalent doses of radiation with ipilimumab
Authors
Heath B. Mackley
Jason Liu
Junjia Zhu
Henry Wagner
Giampaolo Talamo
Todd D. Schell
Colette Pameijer
Rogerio I. Neves
Bryan Anderson
Kathleen M. Kokolus
Jeffrey Sivik
Carol A. Mallon
Kristian M. Koller
Joseph J. Drabick
Publication date
01-06-2017
Publisher
Springer Berlin Heidelberg
Published in
Journal of Radiation Oncology / Issue 2/2017
Print ISSN: 1948-7894
Electronic ISSN: 1948-7908
DOI
https://doi.org/10.1007/s13566-017-0305-8

Other articles of this Issue 2/2017

Journal of Radiation Oncology 2/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine